Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report

Cyclin-dependent kinase 4/6 inhibitors are promising candidates for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, current international guidelines recommend endocrine therapy alone or with HER2-targeted therapy to treat HER2-positive and hormone recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Maoben, Cai, Liangzhen, Chen, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270483/
https://www.ncbi.nlm.nih.gov/pubmed/37327257
http://dx.doi.org/10.1097/MD.0000000000033975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270483/
https://www.ncbi.nlm.nih.gov/pubmed/37327257
http://dx.doi.org/10.1097/MD.0000000000033975

Ejemplares similares